OPINION ARTICLE

How to prevent the next Marathon Pharmaceuticals [version 1; peer review: 2 approved, 1 approved with reservations]

Frank S. David , Richa Dixit

Pharmagellan LLC, Milton, MA, , 02186, USA

V1 First published: 17 Jan 2018, 7:74
<https://doi.org/10.12688/f1000research.13678.1>
Latest published: 17 Jan 2018, 7:74
<https://doi.org/10.12688/f1000research.13678.1>

Abstract

In recent years, several drug companies have exploited U.S. regulatory policies to acquire exclusive rights to cheap therapies and substantially raise their prices, and Federal agencies and state governments are exploring various ways to prevent or punish such behavior in the future. Among these cases, however, Marathon Pharmaceuticals' handling of Emflaza (deflazacort) is unique, because the drug was previously only available abroad, and was never previously sold in the U.S. before the company obtained FDA approval for it. Thus, laws and policies designed to address price hikes on already-marketed drugs are unlikely to prevent additional Marathon-like scenarios. In this article, we describe in more detail the unique features of Emflaza compared with these other recent cases of drug price increases, determine the likelihood that similar situations will arise in the future, and explore legislative and administrative options to specifically prevent such behavior.

Keywords

FDA, orphan, pharmaceutical, price, regulation

Open Peer Review

Approval Status

	1	2	3
version 1			
17 Jan 2018	view	view	view

1. **Alexander Tabarrok** , George Mason University, Fairfax, USA
2. **Rena M. Conti**, The University of Chicago, Chicago, USA
3. **John L. LaMattina**, PureTech Health, Boston, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Frank S. David (frank@pharmagellan.com)

Author roles: **David FS:** Conceptualization, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Dixit R:** Data Curation, Investigation, Writing – Review & Editing

Competing interests: The authors work for Pharmagellan, a pharmaceutical consulting firm. Neither author has ever been employed as a consultant to any of the companies named in this article, nor does either author have any current or prior investments in any of the named companies.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 David FS and Dixit R. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: David FS and Dixit R. **How to prevent the next Marathon Pharmaceuticals [version 1; peer review: 2 approved, 1 approved with reservations]** F1000Research 2018, 7:74 <https://doi.org/10.12688/f1000research.13678.1>

First published: 17 Jan 2018, 7:74 <https://doi.org/10.12688/f1000research.13678.1>

Introduction

When Marathon Pharmaceuticals obtained U.S. approval for Emflaza (deflazacort) in Duchenne's muscular dystrophy (DMD) in 2017, legislators and industry critics vilified the company's plan to price the drug at \$89,000 per year – not for the high cost *per se*, but for allegedly taking unfair advantage of U.S. regulatory and pricing policies to profit handsomely from a decades-old drug available abroad for under \$5 a day.

Although Marathon gained the public's attention in the wake of several other high-profile cases of alleged drug pricing misconduct, this case is actually unique. Unlike firms that have acquired U.S.-marketed agents and then hiked their prices, Marathon gained FDA approval of a drug that was already commercialized abroad, but not in the U.S., then set a U.S. price far higher than the international one. This distinction does not automatically exonerate Marathon, but it highlights a special challenge for regulators and policy-makers seeking to balance access with affordability. It also suggests that there may not be a "one size fits all" approach to punishing and/or preventing companies that engage in the broad range of improper drug pricing behaviors that have been seen to date.

The details of the Marathon case raise three questions. First, what specific aspects of the company's behavior were inappropriate, and distinguish Marathon from other companies that launch high-priced drugs in the U.S.? Second, how prevalent and important are future scenarios like Emflaza likely to be? And finally, what legislative, administrative, and non-policy approaches might effectively prevent and/or punish similar activities?

Distinguishing Emflaza from "appropriate" orphan drugs

Deflazacort, a synthetic corticosteroid originally developed by Merrell Dow Pharmaceuticals, has been available since the 1990s outside the U.S. In 1996, preliminary data in 196 DMD patients showed it was comparably effective to prednisone, but had fewer side effects.¹ Since then, physicians outside the U.S. have prescribed it off-label for DMD, and some American patients have reportedly obtained it from abroad, as permitted under FDA's personal importation policies.^a Marathon Pharmaceuticals purchased the rights to deflazacort, completed the data analysis², and received FDA approval for the drug (now called Emflaza) in February 2017.^b

Marathon's announcement that it intended to raise Emflaza's U.S. price 60-fold compared with its price in the U.K. attracted **substantial scrutiny and censure**. Experts estimate Marathon spent about \$50M, and possibly far less, to acquire deflazacort and

conduct limited additional research. In return for that relatively meager investment, the company was rewarded with seven years of market exclusivity under the Orphan Drug Act for a drug that could earn over \$400M annually.

Superficially, Emflaza invites comparison with other recent examples of exorbitant drug price increases taken by companies that invested little to nothing in the therapy's development. For example, in 2013, Marathon itself acquired two FDA-approved cardiac therapies, Nitropress (sodium nitroprusside) and Isuprel (isoproterenol), from Hospira, then increased the prices about 4-fold before selling the drugs to Valeant in 2015, **which immediately further hiked the prices**. And in 2015, Turing Pharmaceuticals acquired Daraprim (pyrimethamine), a drug for toxoplasmosis and other infectious diseases, and within months **raised the price over 50-fold**. In these cases, like with Emflaza, a company reaped outsized returns by substantially increasing the price on a marketed drug that was discovered long ago by another firm.

But Marathon is distinct from these other examples of egregious price increases because before the company gained approval for Emflaza, U.S. physicians could not prescribe deflazacort to DMD patients. By submitting previously unpublished data on the drug for FDA regulatory review, Marathon enabled Americans to easily obtain a clinically useful therapy that was previously inaccessible through normal channels. This is in stark contrast to the examples cited above, as well as other recent cases of excessive price hikes, like **cycloserine**, Duexis (ibuprofen and famotidine)³, **Keveyis** (daranide), and **Vimovo** (esomeprazole and naproxen) – because in all of these other cases, American patients already had unfettered access to the drug (or its active ingredients).

The fact that Emflaza was not previously available by prescription in the U.S. does not itself justify Marathon's pricing decision, but it highlights a distinctive aspect of this case compared with the other examples cited above. Marathon certainly benefitted from pricing freedom and regulatory advantages that are intended for novel drugs that require substantial at-risk R&D investment, which was not the case with Emflaza. At the same time, however, there is value to enabling American patients to access deflazacort, an effective drug in an under-served disease area, through a standard prescription, without the hassle and expense of acquiring it from abroad. Emflaza illustrates the tension between protecting Americans from predatory pricing behavior on the part of drug manufacturers and encouraging companies to launch meaningful therapies in the U.S. Thus, this particular scenario is not a clear-cut, routine example of pharmaceutical price-gouging, and may warrant specific attention from legislators and regulators.

Defining the magnitude of the problem

Before considering ways to balance affordability and access in Emflaza-like scenarios, it is worth understanding how common these situations are likely to be in the future. To answer this question, we searched for other "legacy" drugs like deflazacort that

^a U.S. FDA Regulatory Procedures Manual, Ch. 9: Import Operations and Actions.

^b The company subsequently sold the rights to another biotech company, PTC Therapeutics.

are available abroad and have existing off-label data in an orphan indication that might support speedy FDA approval at low cost and risk.^c We focused on orphan drug opportunities because these are most likely to be attractive to biotechs seeking to pursue this strategy: published data from a small trial may suffice for FDA approval, without the need for additional studies; high prices for rare diseases therapies in the U.S. are common, and rarely encounter backlash from payers; and market exclusivity under the Orphan Drug Act makes this strategy feasible for “legacy” therapies.

Using the U.K. as a test case, we identified just one approved drug that we believe could support an Emflaza-like strategy: celiprolol, an off-patent beta-blocker originally developed by Rhône-Poulenc and available cheaply abroad. Published data show that celiprolol prophylaxis significantly reduces arterial rupture and dissection in vascular Ehlers-Danlos syndrome (vEDS), a genetic collagen disorder.⁴ Thus, we found it highly possible that a firm could obtain the rights to the drug and data, garner FDA approval with little or no additional R&D expense, raise the price substantially over its current U.K. price, and gain orphan drug market exclusivity. In fact, during the preparation of this article we found that a biotech firm, Acer Therapeutics, had already obtained exclusive rights to celiprolol’s vEDS data, and **intends to file for FDA approval** for the drug (to be called Edsivo) in early 2018, having disclosed no plans for additional clinical trials. Although we analyzed just one non-U.S. country for illustrative purposes, we believe our results suggest that future scenarios directly analogous to Emflaza are possible, but unlikely to be frequent.

Preventing (or punishing) the next Marathon

Emflaza represents a special case of the general problem of companies taking egregious price increases on old drugs, because it involves a therapy not previously approved by the FDA. Thus, recent state and Federal activities aimed at **curbing high prices on off-patent drugs that lack generic competitors** or **large price increases on already-approved agents** will not prevent or punish future Emflaza-like scenarios.

The most effective and least burdensome approach to prevent other firms from copying Marathon’s Emflaza strategy would likely involve alterations to FDA’s existing rules on personal importation.^d Americans are currently permitted to import drugs

for non-serious conditions for personal use if they are “not known to represent a significant health risk”. For “serious” conditions, importation of drugs deemed safe is allowed for personal use only if the drug is neither available nor promoted commercially in the U.S. Refining these criteria to allow Americans to import generics in certain situations where a drug with the same active ingredient is already available in the U.S. – for example, if the generic was launched abroad before the first FDA approval – would permit continued importation of drugs like deflazacort and celiprolol, and thus eliminate the incentive for future companies to take a similar approach. At the same time, such a change would not jeopardize the incentives for drug developers to invest in R&D to develop *bona fide* new therapies and bring them to the U.S. market.

Other options to prevent or punish firms pursuing Marathon’s Emflaza strategy are also theoretically possible, but may be more challenging to implement. It is extremely difficult to define criteria that could allow FDA to block drugs like Emflaza while still approving “legitimate” drugs applying for U.S. market access (based, for example, on an (arbitrary) minimum amount of R&D investment), and in the absence of such a definition, providing FDA with broad latitude to refuse approval to drugs like Emflaza on a case-by-case basis – a sort of **“I know it when I see it”** approach to drug price gamesmanship – **is unlikely to withstand legal scrutiny**. FDA could also enact policies to automatically grant FDA approval to drugs already available outside the U.S., but versions of such “reciprocal approval” policies proposed to date could have undesirable safety implications for American patients that have not been fully explored.⁵ And on the pricing side, although there has been significant recent effort in state legislatures to control price increases on drugs already available in the U.S., there has been scant progress on fairly controlling launch prices of new drugs, which is the key issue for Emflaza.⁶

Conclusions

Although pharmaceutical industry critics commonly lump together various drug price scandals, there are important differences between them that may require, in some cases, bespoke solutions. Marathon Pharmaceuticals illustrates a very specific challenge for legislators and regulators: the potential for companies to gain FDA approval for old drugs available outside the U.S., often under policies intended to support innovative R&D in rare diseases, and then take advantage of the permissive American drug pricing environment to substantially raise their prices. This situation, though likely to be rare in the future, will not be prevented by most of the drug pricing policies currently under consideration at the state and Federal level, and thus may warrant focused attention and a customized approach. Among several potential solutions, a change to FDA’s personal importation policies is most likely to prevent future Emflaza-like scenarios while having little to no impact on the broader U.S. system that rewards drug companies for investing in risky, expensive R&D in clinically important new therapies.

Competing interests

The authors work for Pharmagellan, a pharmaceutical consulting firm. Neither author has ever been employed as a consultant to

^c On February 18, 2017, we downloaded complete lists of drugs approved in the U.S. (2,610) and U.K. (1,879) from <https://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm> and <https://www.medicines.org.uk/emc/browse-ingredients>, respectively. We used text matching and manual curation to identify active ingredients available only in the U.K., eliminating those that were already approved or generally recognized as safe by FDA (and alternate salt forms thereof) or available over the counter in the U.K. We also eliminated various non-therapeutic agents, including diagnostics, cosmetics, food additives, allergy testing antigens, and herbal and nutritional agents (including oils and vitamins). Finally, we excluded vaccines, biologics, cancer therapies, and any drug under active development by its originating company. For the remaining 133 drugs (see **Supplementary File 1**), we searched clinicaltrials.gov and PubMed for positive efficacy data in a new (currently off-label) orphan indication.

^d U.S. FDA Regulatory Procedures Manual, Ch. 9: Import Operations and Actions.

any of the companies named in this article, nor does either author have any current or prior investments in any of the named companies.

Grant information

The author(s) declare that no grants were involved in supporting this work.

Acknowledgements

We thank Frank Provenzano for assisting with initial data capture and analysis, and Julie Lin, Mark Lindsay, Robert Nussbaum, Lisa Rosenbaum, and Rachel Sachs for providing helpful comments during the preparation of this manuscript. We also thank two anonymous reviewers at *Annals of Internal Medicine*, whose helpful suggestions led us to make substantial improvements to this article.

Supplementary material

Supplementary File 1: Potential future “Emflaza-like” opportunities subjected to further analysis. Active ingredients available by prescription in the U.K., but not the U.S., on February 18, 2017, that we analyzed manually (N=133). See text for details.

[Click here to access the data.](#)

References

1. Brooke MH: **A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity [abstract].** *Neurology*. 1996; **46**: A476. [Reference Source](#)
2. Griggs RC, Miller JP, Greenberg CR, *et al.*: **Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.** *Neurology*. 2016; **87**(20): 2123–2131. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Hakim A, Ross JS: **High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis.** *JAMA Intern Med*. 2017; **177**(3): 305–306. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Ong KT, Perdu J, De Backer J, *et al.*: **Effect of celirolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.** *Lancet*. 2010; **376**(9751): 1476–1484. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Larochelle M, Downing NS, Ross JS, *et al.*: **Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study.** *BMJ Open*. 2017; **7**(2): e014582. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Berman A, Lee T, Pan A, *et al.*: **Curbing unfair drug prices: A primer for states.** Yale Global Health Justice Partnership, August 2017. [Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 22 March 2018

<https://doi.org/10.5256/f1000research.14858.r32159>

© 2018 LaMattina J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

John L. LaMattina

PureTech Health, Boston, MA, USA

The authors discuss an important issue regarding the pricing of drugs. The issue is presented clearly and concisely, and is put in the context of other drug pricing situations where egregious prices are being charged. The authors then propose a solution to prevent such an example from occurring in the future.

It is important for this paper to be indexed as it will spark a debate about how to prevent a company like Marathon from exploiting loopholes in the US orphan drug approvals process. The Emflaza case is one where a company is charging far too high a price for an important DMD drug which has been available for decades in Europe for far less money. Furthermore, the authors show that this is not a unique situation and that it is likely to be repeated by another company. Thus, a solution is needed.

The authors propose a potential solution which should be aired and debated. Thus, I fully endorse indexing of this paper.

Having said that, I am not fully on board with the authors' solution. Marathon DID spend \$50 million on clinical studies to prove the medical viability of Emflaza in DMD patients. Yes, the drug is being used off-label in Europe for DMD, but have studies been published justifying its use? If yes, how vigorous are these studies? Depending on the answers to these questions, one could argue that Marathon did a service for physicians and patients by carrying out a phase 3 program that was of sufficient rigor to garner FDA approval.

The authors' solution could work had the NIH carried out these studies and proved the value of Emflaza, thereby justifying the decision to allow Americans to import generics.

Again, my questions only serve to justify indexing of this paper to spur such debate.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 21 February 2018

<https://doi.org/10.5256/f1000research.14858.r30139>

© 2018 Conti R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rena M. Conti

Department of Public Health Sciences, The University of Chicago, Chicago, IL, USA

On the topic of high drug pricing in the US, the authors present an interesting case and thoughtfully discuss its potential implications.

I appreciate their attempt to quantify the prevalence of future potential cases, but felt this effort could have been more systematic and involved other OECD countries.

On motivation, I think it would have been preferable article construction to start with the problem of the pricing of new drugs in the US, particularly orphans, and then located this as a "special" case.

Generally, the authors could have better described the tradeoffs presented in this case regarding access - entry facilitates wider access to a drug that may help American patients suffering from disease, but also creates access and affordability concerns due to the aggressive pricing practices of its manufacturer.

Within this context, the authors insight that this case highlights the special role the FDA may play in altering pricing incentives drug manufacturers face in the US is good and particularly helpful.

Some of the terminology used in the article to discuss the current political debate regarding high prices - notably the public pursuit of "punishing" manufacturers for high prices - is a bit too dismissive and could be revised. Besides from naming and shaming through the press and Congressional hearings, there has been little "punishment" doled out to manufacturers that pursue such aggressive pricing behavior. What punishment exists is related to pricing practices that are specifically illegal as defined by laws and statutes. The main point here should be that the manufacturer's aggressive pricing practices may hurt American patients' access to care and presents real tradeoffs to payers; what to do about this, if anything, is a real concern for patients,

their families and policymakers.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Health economics, pharmaceutical policy

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 24 January 2018

<https://doi.org/10.5256/f1000research.14858.r30142>

© 2018 Tabarrok A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alexander Tabarrok

Department of Economics, George Mason University, Fairfax, VA, USA

Massive increases in the prices of some drugs have generated significant outrage and media attention. Most infamously, Turing Pharmaceutical's increase in the price of Daraprim from \$13.50 to \$750 made headlines around the world. In part, no doubt, because the antics of Turing CEO Martin Shkreli made him an impossible to ignore villain straight out of central casting.

In this paper, David and Dixit look at a seemingly similar case, Marathon Pharmaceutical's decision to price Emflaza at \$89,000 a year when it is available elsewhere in the world at a price on the order of \$1500 a year. David and Dixit caution that the two cases need to be distinguished because prior to Marathon, Emfalza was not for sale in the United States at any price. Marathon performed a useful service in seeking and obtaining FDA approval and there has to be a balancing of costs and benefits if we want to continue to incentivize firms to look for other pharmaceuticals from around the world and make them available in the United States.

I agree with David and Dixit's analysis but I would go further. While David and Dixit suggest that we need "bespoke solutions" I worry that in trying to solve every problem we will create a mass of regulations that raise costs and harm American patients overall. We need to look beyond the headlines at the bigger picture.

Although a handful of generics have seen extreme increases in prices, the prices of generics overall have been falling. The Department of Health and Human Services in 2016 concluded, for example, that big price increases were confined to small markets and that overall total spending and prices were falling.

<https://aspe.hhs.gov/pdf-report/understanding-recent-trends-generic-drug-prices>

More references here:

<http://marginalrevolution.com/marginalrevolution/2016/02/the-good-news-on-generic-drugs.html>

The baby in this case is much bigger and more valuable than the bathwater so even though massive increase in prices feel unjust and unfair we need to be extra careful not to throw the baby out with the bathwater. The rules governing the US generic markets are working very well. US prices for generics are low by world standards and availability is high.

Branded pharmaceuticals in the United States are, of course, very expensive. But what needs to be stressed is that by a time a drug is approved, patents last only about 10-15 years and then prices fall rapidly with generic competition. Moreover, a large majority of prescriptions are for generics. Even more importantly, it's vital that we continue to produce new drugs to reduce morbidity and mortality. In any welfare comparison, high prices are a small price to pay for better life-saving and live-improving medicines.

Thus, I agree with the David and Dixit analysis but suggest that broadening the picture would strengthen their argument even further.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: economics, pharmaceutical regulation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research